Conditions: Sickle Cell Disease
Keywords: Sickle Cell Disease
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 15
Healthy volunteers: no

Brief summary:
This Phase 1/Phase 2 study will evaluate GMI-1070, a pan-selectin inhibitor, in adults with stable sickle cell disease. The study will assess safety, pharmacokinetics, and microvascular effects of intravenous GMI-1070 in the outpatient setting.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: GMI-1070
Intervention descriptions: intervention 1: Intravenous GMI-1070 given as two doses over the course of one day

Protocol document: